دورية أكاديمية
Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma.
| العنوان: | Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma. |
|---|---|
| المؤلفون: | Hwang EC; Department of Urology, Chonnam National University Medical School, Chonnam National University Hwasun Hospital, Hwasun, Korea, South., Sathianathen NJ, Jung JH, Kim MH, Dahm P, Risk MC |
| المصدر: | The Cochrane database of systematic reviews [Cochrane Database Syst Rev] 2019 May 18; Vol. 5. Cochrane AN: CD013160. Date of Electronic Publication: 2019 May 18. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Systematic Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley Country of Publication: England NLM ID: 100909747 Publication Model: Electronic Cited Medium: Internet ISSN: 1469-493X (Electronic) Linking ISSN: 13616137 NLM ISO Abbreviation: Cochrane Database Syst Rev Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2004- : Chichester, West Sussex, England : Wiley Original Publication: Oxford, U.K. ; Vista, CA : Update Software, |
| مواضيع طبية MeSH: | Administration, Intravesical*, Antineoplastic Agents/*administration & dosage , Carcinoma/*drug therapy , Ureteral Neoplasms/*drug therapy, Antineoplastic Agents/therapeutic use ; Humans ; Nephroureterectomy ; Randomized Controlled Trials as Topic ; Treatment Outcome |
| مستخلص: | Background: Single-dose, postoperative intravesical chemotherapy reduces the risk of bladder cancer recurrence after transurethral resection of bladder tumours. However, there is limited evidence whether single-dose intravesical chemotherapy is similarly effective at preventing bladder cancer recurrence after nephroureterectomy. Objectives: To assess the effects of single-dose intravesical chemotherapy instillation after nephroureterectomy for upper tract urothelial carcinoma. Search Methods: We performed a comprehensive literature search using multiple databases (MEDLINE, Cochrane Library, Embase, Scopus, Web of Science, and LILACS), trials registries, other sources of grey literature, and conference proceedings published up to April 15 2019, with no restrictions on language or status of publication. Selection Criteria: We included randomised controlled trials in which participants either received or did not receive single-dose intravesical chemotherapy instillation after nephroureterectomy. Data Collection and Analysis: Two review authors screened and independently assessed studies and extracted data from included studies. We performed statistical analyses using a random-effects model. We rated the certainty of evidence according to the GRADE approach. Main Results: The search identified two studies (a multicenter study from Japan and the United Kingdom) with 361 participants.Primary outcomesOur results indicate that single-dose intravesical chemotherapy instillation may reduce the risk of bladder cancer recurrence over time compared to no instillation (hazard ratio [HR]: 0.51, 95% confidence interval [CI]: 0.32 to 0.82, low-certainty evidence). After 12 months follow-up, this would result in 127 fewer bladder cancer recurrences (95% CI: 182 to 44 fewer bladder cancer recurrences) per 1000 participants. We downgraded the certainty of evidence by two levels due to study limitations and imprecision.We found no trials that reported on the outcomes of time to death from upper tract urothelial carcinoma. The effect of single-dose intravesical chemotherapy instillation on serious adverse events is uncertain (risk ratio [RR]: not estimable, 95% CI: not estimable, there were no events, very low-certainty evidence). We downgraded the certainty of evidence by one level due to study limitations and by two levels due to imprecision.Secondary outcomesWe found no trials that reported on the outcomes of time to death from any cause and participants' disease-specific quality of life. The effect of single-dose intravesical chemotherapy instillation on minor adverse events is uncertain (risk ratio [RR]: not estimable, 95% CI: not estimable, there were no events, very low-certainty evidence). We downgraded the certainty of evidence by one level due to study limitations and by two levels due to imprecision. Authors' Conclusions: For patients who have undergone nephroureterectomy for upper tract urothelial carcinoma, single-dose intravesical chemotherapy instillation may reduce bladder cancer recurrence after nephroureterectomy. However, we are uncertain as to the risk of serious (and minor) adverse events. We found no evidence for the outcome of time to death from upper tract urothelial carcinoma. We were unable to conduct any of the preplanned subgroup analyses, particularly those based on operative approach, pathologic stage, and method of bladder cuff excision. |
| References: | World J Urol. 2017 Mar;35(3):337-353. (PMID: 27101100) Jpn J Clin Oncol. 2018 Jan 1;48(1):94-97. (PMID: 29136187) J BUON. 2015 Sep-Oct;20(5):1229-38. (PMID: 26537069) Lancet. 1993 Oct 30;342(8879):1087-8. (PMID: 8105314) Clin Genitourin Cancer. 2017 Dec;15(6):e1055-e1061. (PMID: 28802888) Eur Urol. 2013 Oct;64(4):683-4. (PMID: 23998501) J Clin Epidemiol. 2011 Dec;64(12):1283-93. (PMID: 21839614) J Urol. 2004 Jun;171(6 Pt 1):2186-90, quiz 2435. (PMID: 15126782) Eur J Cancer. 2008 Sep;44(13):1793-8. (PMID: 18599286) J Clin Oncol. 2010 Feb 1;28(4):543-8. (PMID: 19841330) Eur Urol. 2014 Mar;65(3):650-8. (PMID: 24070577) Eur Urol. 2011 Oct;60(4):703-10. (PMID: 21684068) Health Qual Life Outcomes. 2013 Jul 01;11:109. (PMID: 23815754) Stat Med. 1998 Dec 30;17(24):2815-34. (PMID: 9921604) Int J Clin Pract. 2013 May;67(5):435-48. (PMID: 23137019) Stat Med. 2002 Jun 15;21(11):1539-58. (PMID: 12111919) PLoS Med. 2009 Jul 21;6(7):e1000100. (PMID: 19621070) J Clin Oncol. 2013 Apr 10;31(11):1422-7. (PMID: 23460707) J Chemother. 2015 Aug;27(4):195-200. (PMID: 25968487) Expert Opin Pharmacother. 2010 Apr;11(6):947-58. (PMID: 20205607) Clin Cancer Res. 2005 Sep 15;11(18):6512-9. (PMID: 16166427) Jpn J Clin Oncol. 2013 Nov;43(11):1139-44. (PMID: 24006504) Cancer. 2007 Oct 15;110(8):1715-22. (PMID: 17724728) Eur Urol. 2014 Aug;66(2):253-62. (PMID: 24472711) BJU Int. 2009 Nov;104(10):1436-40. (PMID: 19689473) Int J Urol. 2015 Jan;22(1):3-13. (PMID: 25243652) Urology. 1998 Oct;52(4):594-601. (PMID: 9763077) Trials. 2007 Jun 07;8:16. (PMID: 17555582) Int J Clin Exp Med. 2014 Dec 15;7(12):4734-46. (PMID: 25663970) Res Synth Methods. 2013 Mar;4(1):49-62. (PMID: 26053539) Contemp Clin Trials Commun. 2018 Feb 28;9:121-129. (PMID: 29696234) Urol Oncol. 2011 Mar-Apr;29(2):130-6. (PMID: 19762256) Eur Urol. 2013 Sep;64(3):421-30. (PMID: 23830475) BMC Med Res Methodol. 2005 Apr 20;5:13. (PMID: 15840177) Int J Urol. 2001 May;8(5):212-6. (PMID: 11328420) Urol Oncol. 2017 Mar;35(3):113.e1-113.e7. (PMID: 27884539) Eur Urol. 2006 Mar;49(3):466-5; discussion 475-7. (PMID: 16442208) BMC Cancer. 2015 Mar 18;15:149. (PMID: 25886012) Korean J Urol. 2014 Jul;55(7):453-9. (PMID: 25045443) Eur Urol. 2018 Jan;73(1):111-122. (PMID: 28867446) CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. (PMID: 24399786) Eur Urol. 2016 Feb;69(2):231-44. (PMID: 26091833) Urol Clin North Am. 2013 May;40(2):197-210. (PMID: 23540778) Urology. 2013 May;81(5):972-7. (PMID: 23523292) BMJ. 2008 May 3;336(7651):995-8. (PMID: 18456631) J Urol. 2013 Apr;189(4):1214-21. (PMID: 23023150) J Clin Epidemiol. 2011 Apr;64(4):383-94. (PMID: 21195583) Cochrane Database Syst Rev. 2019 May 18;5:CD013160. (PMID: 31102534) J Natl Compr Canc Netw. 2013 Apr 1;11(4):477-84. (PMID: 23584348) Urol Int. 2013;91(3):291-6. (PMID: 23948770) BMJ. 2003 Sep 6;327(7414):557-60. (PMID: 12958120) |
| المشرفين على المادة: | 0 (Antineoplastic Agents) |
| تواريخ الأحداث: | Date Created: 20190519 Date Completed: 20190910 Latest Revision: 20231227 |
| رمز التحديث: | 20231227 |
| مُعرف محوري في PubMed: | PMC6525634 |
| DOI: | 10.1002/14651858.CD013160.pub2 |
| PMID: | 31102534 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1469-493X |
|---|---|
| DOI: | 10.1002/14651858.CD013160.pub2 |